1. Temocillin susceptibility among Enterobacterales strains recovered from blood culture in France.
- Author
-
Farfour E, Si Larbi AG, Cattoir V, Corvec S, Guillard T, Grillon A, Isnard C, Mérens A, Degand N, Billard-Pomares T, Fournier D, Bille E, Le Brun C, Plouzeau C, Flevin E, Yin N, Woerther PL, Lourtet J, Lesprit P, and Le Monnier A
- Subjects
- Dose-Response Relationship, Drug, Enterobacteriaceae Infections epidemiology, France epidemiology, Humans, Microbial Sensitivity Tests, Anti-Bacterial Agents pharmacology, Drug Resistance, Bacterial, Enterobacteriaceae drug effects, Enterobacteriaceae Infections microbiology, Penicillins pharmacology
- Abstract
Temocillin is used for several years in some European countries but, only since 2015 in France. We assessed the susceptibility of Enterobacterales strains isolated from blood culture 1 year before (2014) and 2 years after (2017) its use in France. 1,387 strains were included by 17 clinical laboratories located throughout France: 363 in 2014 and 1,024 in 2017. The rate of resistance to temocillin was 4.6% and 26.7% in 3rd generation cephalosporin (3GC) susceptible and resistant strains respectively. Cephalosporinase-overproducer (COPE) strains were significantly more resistant to temocillin (37.7%) than ESBL-producer (ESBL-PE) (23.5%) (P < 0.01). The rate of temocillin resistance was correlated to the number of inactive beta-lactams. The rate of resistance to temocillin trend to increase from 13.9% in 2014 to 23.9% in 2017 (P < 0.01). Temocillin remains highly active against Enterobacterales but the trend in resistance should be assessed over time., Competing Interests: Competing interest The temocillin Etest strips (bioMérieux, Lyon, France) were provided without charge by Eumedica pharmaceutical., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF